USA

C4 Therapeutics will use its proprietary TORPEDO platform to design the degrader payloads, while Roche will oversee antibody selection, conjugation chemistry, preclinical testing, and clinical development

The contract includes multiyear options that could ultimately deliver up to USD 482 million if exercised, enabling Shionogi to establish a dedicated manufacturing facility in the United States.

This setback follows Brinsupri’s unsuccessful phase 2 trial for chronic rhinosinusitis without nasal polyps, which also failed to meet its primary and secondary endpoints at both tested doses.

The Houston subsidiary will now serve as the strategic headquarters, overseeing and expanding collaborations with medical institutions and pharmaceutical companies across the United States.

Central to this deal is TSND-201, also known as methylone, Transcend’s lead experimental drug for post-traumatic stress disorder (PTSD) and other psychiatric conditions.

The acquisition grants Biogen access to two already-marketed medications that generated USD689 million in sales last year.

The Raptor™ platform uses advanced genetic engineering tools to produce recombinant biologics inside eggs.

For MSD, this acquisition is part of a broader strategy to diversify its pipeline before its blockbuster immunotherapy Keytruda loses patent protection.

Avlayah’s approval validates Denali’s blood-brain barrier shuttle technology, which the company now applies across five clinical programs targeting Alzheimer’s disease, Parkinson’s disease, and Sanfilippo syndrome type A, among others.